FORMOTEROL/BUDESONIDE/GLYCOPYRRONIUM INHALER (Trixeo AerospaceĀ®)

Clinical Indication

Moderate to severe COPD

Comments

Reviewed by the Respiratory Prescribing Group May 2022

Date of classification

June 2022

Do not prescribe

Drugs not recommended for use in LLR because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety